アフリカ分子ポイントオブケア検査(NAAT 使用)市場 – 業界動向と 2028 年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

アフリカ分子ポイントオブケア検査(NAAT 使用)市場 – 業界動向と 2028 年までの予測

  • Medical Devices
  • Published Report
  • Aug 2022
  • Country Level
  • 350 ページ
  • テーブル数: 287
  • 図の数: 42

アフリカ分子ポイントオブケア検査(NAAT を使用)市場、製品別(機器および消耗品と試薬)、適応症別(呼吸器感染症検査、性感染症(STI)検査、胃腸管感染症検査、その他)、エンドユーザー別(研究所、病院、診療所、外来センター、在宅ケア、介護施設、その他)、検査モード別(処方箋に基づく検査および OTC 検査)、流通チャネル別(病院薬局、小売薬局、オンライン薬局)– 2028 年までの業界動向と予測。

アフリカ分子ポイントオブケア検査(NAAT 使用)市場分析と洞察

アフリカの分子ポイントオブケア検査(NAAT を使用)市場は、医療施設やインフラの改善、病院、研究所、診療所でのポイントオブケア検査の導入により、市場の発展を促進するために成長すると予想されています。分子ポイントオブケア検査(NAAT を使用)市場の成長を促進すると予想されるその他の要因には、感染症の蔓延の増加が含まれます。

熟練した専門家の不足やカスタマイズされた分子ポイントオブケア検査(NAATを使用)の高コストなどの他の要因は、アフリカの分子ポイントオブケア検査(NAATを使用)市場の成長を妨げています。一方、医療費の増加と病院が発達した新興国は、アフリカの分子ポイントオブケア検査(NAATを使用)市場の成長の機会として機能します。

Data Bridge Market Research は、アフリカの分子ポイントオブケア検査 (NAAT を使用) 市場は 2021 年から 2028 年にかけて 5.8% の CAGR で成長すると分析しています。

レポートメトリック

詳細

予測期間

2021年から2028年

基準年

2020

歴史的な年

2019

定量単位

売上高は百万米ドル、価格は米ドル

対象セグメント

製品別(器具、消耗品、試薬)、適応症別(呼吸器感染症検査、性感染症(STI)検査、消化管感染症検査、その他)、エンドユーザー別(研究所、病院、診療所、外来センター、在宅ケア、介護施設、その他)、検査方法別(処方箋に基づく検査およびOTC検査)、流通チャネル別(病院薬局、小売薬局、オンライン薬局)

対象国

南アフリカ、ケニア、ナイジェリア、その他のアフリカ

対象となる市場プレーヤー

Abbott、F.Hoffmann-La Roche Ltd.、Danaher、Thermo Fisher Scientific Inc、Sysmex Corporation、Meridian Bioscience、BD、Biomérieux Sa、Qiagen、Quidel Corporation、Bio-Rad Laboratories, Inc.、PerkinElmer Inc.

アフリカ分子ポイントオブケア検査(NAAT 使用)市場の市場定義

POCT は、患者の近くで実施できる検査として特徴付けられ、結果とモニタリングを含め、医療上の決定を即座に行うことができます。現在臨床使用されている POCT デバイスは、核酸増幅技術 (NAAT) に基づいており、ここでは第 2 世代デバイスと定義されています。これらのプラットフォームは、第 1 世代 POCT と比較して、一般的に感度が向上しており、通常は 60 ~ 90% 向上しており、設置面積が約 30cm x 30cm のポータブル機器が必要です。これらの機器は基本的に、NAAT 技術を使用して HIV、HPV、呼吸器疾患などのさまざまな疾患を分子レベルで検出するために使用されます。NAAT は、病原体の DNA または RNA を検出することで病原体を特定できる核酸増幅技術です。

世界的なパンデミックの中で、NAATの感度とPOCTアッセイの使いやすさを相乗的に利用しようとする試みとして、COVID-19のスクリーニングと診断を迅速化するために小型化されたNAATベースのPOCTデバイスとアッセイが考案され、これも市場の成長を後押ししました。

アフリカ分子ポイントオブケア検査(NAAT 使用)市場動向

 このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。

ドライバー

  • 慢性疾患の罹患率の増加

健康の衰えは加齢とともに始まるというのはよく知られた事実です。慢性疾患の割合が時間とともに増加するにつれて、疾患の割合に関連する要因も増加します。肥満/太りすぎの人口が多いことも、世界中のさまざまな地域で慢性疾患の有病率を増加させています。HPV、STI、TBなどの慢性疾患の増加により、人々はNAATベースのポイントオブケアと検査用製品を選択するようになりました。したがって、これは今後数年間でアフリカの分子ポイントオブケア検査(NAATを使用)市場の成長を促進する可能性があります。

  • 診断受診率の向上

がん、貧血、2 型糖尿病などの慢性疾患の診断成功率の増加に伴い、改善された医療専門家は、地域の診断率の向上を考慮して、検査を実施するための専門家向けの定期的なトレーニング セッションを提供しています。疾患の負担が増加するにつれて、診断率も増加しています。診断の進歩により、診断を受ける人の割合も増加しています。

  • 在宅ケア検査の好感度が上昇

在宅医療の好みにより、適切な場所と時間に臨床情報を入手できるようになります。また、品質を確保することで、間違いを減らし、安全性を高めることにも役立ちます。また、医療上の緊急事態が発生した場合、高齢者の助けにもなります。ポイントオブケア検査の利点に対処するために、医療分野では多くの戦略的変更が行われてきました。世界保健機関 (WHO) によると、65 歳以上の人口は 2010 年の推定 5 億 2,400 万人から 2050 年にはおよそ 15 億人に増加すると予想されており、その増加の大部分は先進国で発生します。

機会

  • 市場参加者による戦略的取り組み

慢性および非慢性疾患の負担が世界的に増加し、アフリカとアジアの高齢者人口が増加したことにより、より有効で時間のかからない分子ポイントオブケア検査用の新しいキットとソリューションの開発に対する需要が高まっています。この地域で診断とスクリーニングを提供するために、市場のプレーヤーは、キットと機器を通じてアフリカの人々に質の高いケアを提供するために、互いに提携し、合意しています。

  • RisE 医療費

医療費とインフラストラクチャの増加により、患者は手間をかけずに高度な治療を受け、より適切な診断、処置、治療を受け、回復を早めることができます。ポイントオブケア検査機器は、POC ソフトウェアとソリューションを使用してさまざまな病気を検出し、治療計画をサポートするのに役立ちます。医療費は、自己負担(治療費を負担する人々)、政府支出、健康保険や非政府組織の活動などの資金源から構成されます。

制約/課題

  • 製品の高コスト

ポイントオブケア検査製品の開発プロセスには、かなりのコストがかかります。コンセプトを確定させる必要があるため、材料を調達する必要があり、リードタイムを考慮することが不可欠です。さらに、デバイス設計が完全に成熟するまでに十分な時間が必要であり、市場に投入して使用できるようになるまで時間がかかるため、プロセスには時間がかかります。

  • 研究所から得られた試​​験結果との整合性の欠如

臨床検査基準の結果と比較すると、NAAT 検査の結果は異なります。臨床検査はより高度で、臨床検査のプロセス、プロトコル、科学に従い、効果を正確に分析、検証、文書化するために必要なテクノロジーと完全に統合されています。ただし、POCT/NAAT は正確な結果が不足していることは間違いありません。分子 POCT は標準化を完了できず、その他の重要な基準は標準化とさまざまな必須基準を達成できません。これは、アフリカの分子ポイント オブ ケア検査市場にとって大きな課題です。PoC テストでは、誤った結果が提供される場合があり、テスト結果にばらつきが生じます。

COVID-19後のアフリカ分子ポイントオブケア検査(NAAT使用)市場への影響

COVID-19は、分子ポイントオブケア検査(NAATを使用)市場に大きな影響を与えました。COVID-19は、オンライン販売の進歩と技術の進歩により、分子ポイントオブケア検査(NAATを使用)製品の価格と需要に高いレベルでプラスの影響を与えています。COVID-19パンデミックの発生は、特にさまざまな病院で分子ポイントオブケア検査(NAATを使用)の要件が増加したため、市場の成長にプラスの影響を与えました。COVID-19症例の急増が依然として続いているため、ほとんどの病院では現在、COVID-19治療が優先されており、分子ポイントオブケア検査(NAATを使用)の使用も増加しています。さらに、多くの国際政府や医療機関は、重要な症例での優先度が高いため、これらの製品の供給を支援しています。

最近の動向

  • 2021年11月、F.ホフマン・ラ・ロシュ社は、ロシュがダウ・ジョーンズ・サステナビリティ・インデックスにおいて13年連続で最も持続可能なヘルスケア企業トップ3にランクされたと発表しました。これにより、予測期間中の事業遂行能力と事業拡大が増加しました。
  • 2021年10月、サーモフィッシャーサイエンティフィックコーポレーションは、TaqMan COVId-19テストSARS-COV分子アッセイのFDA承認を取得しました。これにより、同社の製品ポートフォリオが増加し、予測期間中の同社の収益に貢献しました。

アフリカ分子ポイントオブケア検査(NAAT 使用)市場範囲

アフリカの分子ポイントオブケア検査(NAAT 使用)市場は、製品、適応症、エンドユーザー、検査モード、流通チャネルに基づいて 5 つの主要なセグメントに分類されます。これらのセグメントの成長は、業界の市場成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供して、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。

製品

  • 楽器
  • 消耗品および試薬

製品に基づいて、アフリカの分子ポイントオブケア検査(NAAT を使用)市場は、機器と消耗品および試薬に分類されます。

表示

  • 性感染症(STI)検査
  • 呼吸器感染症検査
  • 消化管感染症検査
  • その他

適応症に基づいて、アフリカの分子ポイントオブケア検査(NAAT を使用)市場は、性感染症(STI)検査、呼吸器感染症検査、胃腸管感染症検査、その他に分類されます。

エンドユーザー

  • 研究所
  • 病院
  • クリニック
  • 外来センター
  • ホームケア
  • 介護施設
  • その他

エンドユーザーに基づいて、アフリカの分子ポイントオブケア検査(NAAT を使用)市場は、研究所、病院、診療所、外来センター、在宅ケア、介護施設、その他に分類されます。

テストのモード

  • 処方箋に基づく検査
  • OTC検査

検査方法に基づいて、アフリカの分子ポイントオブケア検査(NAAT を使用)市場は、処方箋に基づく検査と OTC 検査に分類されます

流通チャネル

  • 病院薬局
  • 小売薬局
  • オンライン薬局

分子ポイントオブケア検査(NAAT使用)市場

流通チャネルに基づいて、アフリカの分子ポイントオブケア検査(NAAT を使用)市場は、病院薬局、小売薬局、オンライン薬局に分類されます。

アフリカ分子ポイントオブケア検査(NAAT 使用)市場地域分析/洞察

アフリカの分子ポイントオブケア検査(NAAT を使用)市場が分析され、製品、適応症、エンドユーザー、検査モード、流通チャネルに基づいて市場規模の洞察と傾向が提供されます。

アフリカの分子ポイントオブケア検査(NAAT を使用)市場レポートは、南アフリカ、ケニア、ナイジェリア、およびその他のアフリカ諸国をカバーしています。

南アフリカは、アフリカの分子ポイントオブケア検査(NAAT を使用)市場で、市場シェアと市場収益の点で約 6.1% の CAGR で優位に立っています。予測期間中、南アフリカはその優位性を維持し続けるでしょう。これは、感染症や慢性疾患の蔓延の増加と、医療分野における技術の進歩の進行によるものです。

競争環境とアフリカの分子ポイントオブケア検査(NAAT を使用)市場シェア分析

アフリカの分子ポイント オブ ケア検査 (NAAT を使用) 市場の競争状況は、競合他社に関する詳細を提供します。含まれるコンポーネントは、会社概要、会社の財務、収益、市場の可能性、研究開発への投資、新しい市場イニシアチブ、アフリカでのプレゼンス、生産拠点と施設、会社の長所と短所、製品の発売、規制ガイドライン、ブランド分析、製品の承認、製品のペイロード、アプリケーションの優位性、技術ライフライン曲線です。上記のデータ ポイントは、アフリカの分子ポイント オブ ケア検査 (NAAT を使用) 市場への会社の焦点にのみ関連しています。

アフリカの分子ポイントオブケア検査(NAAT を使用)市場で活動している主要企業としては、Abbott、SD Biosensor、Thermo Fisher Scientific Inc.、INC.、bioMérieux SA、Danaher、Hologic、Inc.、Seegene Inc.、Sysmex Corporation、F. Hoffmann-La Roche Ltd などがあります。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 DISTRIBUTION CHANNEL LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES

4.3.1 CEPHEID

4.3.2 THERMO FISHER SCIENTIFIC INC.

4.3.3 HOLOGIC, INC.

4.3.4 BD

4.3.5 F. HOFFMANN-LA ROCHE LTD

4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY

4.5 PRICE PER POCT INSTRUMENT

4.5.1 NORTH AMERICA

4.5.2 EUROPE

4.5.3 SOUTH ASIA

4.5.4 SOUTH EAST ASIA

4.5.5 MIDDLE EAST

4.5.6 AFRICA

4.6 PRICE PER TEST

4.6.1 NORTH AMERICA

4.6.2 EUROPE

4.6.3 SOUTH ASIA

4.6.4 SOUTH EAST ASIA

4.6.5 MIDDLE EAST

4.6.6 AFRICA

4.7 MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS

4.8 MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI)

4.9 MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS

4.1 MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS

4.11 DISTRIBUTORS

4.11.1 NORTH AMERICA

4.11.2 EUROPE

4.11.3 SOUTH ASIA

4.11.4 SOUTH EAST ASIA

4.11.5 MIDDLE EAST

4.11.6 AFRICA

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES

6.1.2 IMPROVING DIAGNOSIS SEEKING RATE

6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS

6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE

6.1.5 RISING PREFERENCE FOR HOMECARE TESTING

6.2 RESTRAINTS

6.2.1 PRODUCT RECALLS

6.2.2 HIGH COSTS OF PRODUCTS

6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 PANDEMIC OUTBREAK OF COVID-19

6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS

6.4 CHALLENGES

6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

6.4.2 LACK OF ACCESSIBILITY

7 IMPACT OF COVID-19 ON THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY CHAIN

7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19

7.5 CONCLUSION:

8 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 CONSUMABLES & REAGENTS

8.3 INSTRUMENTS

8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)

8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)

9 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION

9.1 OVERVIEW

9.2 RESPIRATORY INFECTIONS TESTING

9.2.1 COVID-19

9.2.2 FLU B

9.2.3 FLU A

9.2.4 RSV

9.2.5 TUBERCULOSIS

9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)

9.2.7 OTHERS

9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING

9.3.1 TV

9.3.2 CT

9.3.3 NG

9.3.4 HPV

9.3.5 HSV

9.3.6 MG

9.3.7 UU

9.3.8 MH

9.3.9 OTHERS

9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING

9.4.1 GROUP B STREPTOCOCCUS

9.4.2 SHIGA TOXIN

9.4.3 H. PYLORI

9.5 OTHERS

10 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER

10.1 OVERVIEW

10.2 LABORATORIES

10.3 HOSPITAL

10.4 CLINICS

10.5 AMBULATORY CENTER

10.6 HOMECARE

10.7 ASSISTED LIVING FACILITIES

10.8 OTHERS

11 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING

11.1 OVERVIEW

11.2 PRESCRIPTION-BASED TESTING

11.3 OTC TESTING

12 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT SALES

12.3 THIRD PARTY DISTRIBUTOR

12.4 ONLINE SALES

13 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION

13.1 AFRICA

13.1.1 SOUTH AFRICA

13.1.2 KENYA

13.1.3 NIGERIA

13.1.4 REST OF AFRICA

14 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 DANAHER

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 THERMO FISHER SCIENTIFIC INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 HOLOGIC, INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 BD

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 F.HOFFMANN-LA-ROCHE LTD.

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENTS

16.6 ABBOTT

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 BINX HEALTH, INC.

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 BIOMERIEUX SA

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 BIO-RAD LABORATORIES, INC.

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 CO-DIAGNOSTICS, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENTS

16.11 GENMARK DIAGNOSTICS, INC

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 GRIFOLS, S.A.

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 LUCIRA HEALTH INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 MERIDIAN BIOSCIENCE

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 OXFORD NANOPORE TECHNOLOGIES

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 PERKIN ELMER INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 QIAGEN

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENTS

16.18 QUANTUMDX GROUP LTD.

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENTS

16.19 QUIDEL CORPORATION

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 RANDOX LABORATORIES LTD.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

16.21 SD BIOSENSOR, INC.

16.21.1 COMPANY SNAPSHOT

16.21.2 PRODUCT PORTFOLIO

16.21.3 RECENT DEVELOPMENT

16.22 SEEGENE INC,

16.22.1 COMPANY SNAPSHOT

16.22.2 REVENUE ANALYSIS

16.22.3 PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)

16.23.1 COMPANY SNAPSHOT

16.23.2 PRODUCT PORTFOLIO

16.23.3 RECENT DEVELOPMENT

16.24 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PRODUCT PORTFOLIO

16.24.4 RECENT DEVELOPMENT

16.25 WONDFO

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

表のリスト

TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)

TABLE 7 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 8 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 9 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 10 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 11 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 12 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 13 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 14 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 15 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 16 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 17 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 18 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 19 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 20 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 21 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 22 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 23 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 24 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 25 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 26 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 27 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 28 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 29 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 30 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 31 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 32 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 33 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 34 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 35 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 36 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 37 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 38 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 39 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 40 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 41 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 42 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 43 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 44 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 45 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 46 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 47 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 48 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 49 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 50 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 51 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 52 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 53 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 54 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 55 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 56 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 57 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 58 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 59 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 60 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 61 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 62 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 63 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 64 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 65 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 66 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 67 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 68 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 69 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 70 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 71 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 72 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 73 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 74 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 75 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 76 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 77 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 78 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 79 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 80 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 81 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 82 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 83 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 84 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 85 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 86 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 87 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 88 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 89 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 90 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 91 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 92 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 93 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 94 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 95 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 96 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 97 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 98 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 99 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 100 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 101 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 102 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 103 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 104 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 105 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 106 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 107 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 108 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 109 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 110 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 111 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 112 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 113 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 114 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 115 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 116 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 117 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 118 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 119 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 120 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 121 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 122 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 123 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 124 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 125 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 126 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 127 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 128 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 129 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 130 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 131 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 132 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 133 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 134 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 135 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 136 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 137 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 138 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 139 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 140 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 141 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 142 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 143 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 144 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 145 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 146 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 147 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 148 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 149 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 150 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 151 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 152 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 153 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 154 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 155 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 156 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 157 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 158 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 159 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 160 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 161 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 162 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 163 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 164 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 165 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 166 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 167 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 168 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 169 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 170 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 171 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 172 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 173 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 174 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 175 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 176 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 177 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 178 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 179 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 180 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 181 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 182 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 183 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 184 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 185 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 186 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 187 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 188 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 189 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 190 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 191 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 192 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 193 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 194 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 195 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 196 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 197 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 198 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 199 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 200 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 201 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 202 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 203 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 204 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 205 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 206 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 207 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 208 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 209 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 210 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 211 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 212 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 213 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 214 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 215 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 216 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 217 DISTRIBUTORS ACROSS NORTH AMERICA

TABLE 218 DISTRIBUTORS ACROSS EUROPE

TABLE 219 DISTRIBUTORS ACROSS SOUTH ASIA

TABLE 220 DISTRIBUTORS ACROSS SOUTH EAST ASIA

TABLE 221 DISTRIBUTORS ACROSS MIDDLE EAST

TABLE 222 DISTRIBUTORS ACROSS AFRICA

TABLE 223 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 224 AFRICA CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 225 AFRICA PEDIATRIC IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 226 AFRICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 227 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 228 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 229 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 230 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 231 AFRICA SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 232 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 233 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 234 AFRICA OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 235 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 236 AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 237 AFRICA HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 238 AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 239 AFRICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 240 AFRICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 241 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 242 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 243 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 244 AFRICA PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 245 AFRICA OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 246 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 247 AFRICA DIRECT SALES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 248 AFRICA THIRD PARTY DISTRIBUTOR IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 249 AFRICA ONLINE SALE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 250 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 251 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 252 AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 253 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 254 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 255 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 256 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 257 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 258 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 259 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 260 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 261 SOUTH AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 262 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 263 SOUTH AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 264 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 265 SOUTH AFRICAGASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 266 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 267 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 268 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 269 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 270 KENYA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 271 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 272 KENYA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 273 KENYA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 274 KENYA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 275 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 276 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 277 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 278 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 279 NIGERIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 280 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 281 NIGERIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 282 NIGERIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 283 NIGERIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 284 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 285 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 286 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 287 REST OF AFRICA & AFRCIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

図表一覧

FIGURE 1 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 2 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION

FIGURE 3 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS

FIGURE 4 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING

FIGURE 8 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID

FIGURE 11 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS SEEKING RATE ARE EXPECTED TO DRIVE THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

FIGURE 16 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016

FIGURE 17 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020

FIGURE 18 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)

FIGURE 19 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 20 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 21 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020

FIGURE 22 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 23 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 24 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 25 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020

FIGURE 26 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 27 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)

FIGURE 28 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020

FIGURE 30 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)

FIGURE 31 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)

FIGURE 32 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE

FIGURE 33 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 34 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 35 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 36 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 37 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 38 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 39 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 40 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 41 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 42 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The Africa Molecular Point of Care Testing (using NAAT) Market will grow at a CAGR of 5.8% by the forecast.
The major players operating in the Africa Molecular Point of Care Testing (using NAAT) Market are Abbott, F.Hoffmann-La Roche Ltd., Danaher, Thermo Fisher Scientific Inc, Sysmex Corporation, Meridian Bioscience, BD, Biomérieux Sa, Qiagen, Quidel Corporation, Bio-Rad Laboratories, Inc., PerkinElmer Inc.
The major countries covered in the Africa Molecular Point of Care Testing (using NAAT) Market are South Africa, Kenya, Nigeria and Rest of Africa.